Laddar populära aktier...
Redeye leaves a comment relating to the announcement of Werfen and its new POC system GEM Premier 70...
Redeye provides a research update on Faron Pharmaceuticals following the company’s recent H1 report.
The independent Data Monitoring Committee (DMC) recommends to proceed the clinical Tumorad-01, with ...
Loihde’s Q2 was better than anticipated. Net sales grew a modest 3% to EUR 35.
At the end of September Beyond Frames internal studio will release “Escaping Wonderland” based on “A...
Redeye concludes that Q2 revenues were weaker than expected, derived from short-term delays and orde...
5% org. sales growth, 7% adj. EBITA growth, neg. cash flow '24e-'26e adj.
Devport levererade en omsättning och resultat för det andra kvartalet i nivå med marknadens förväntn...
Q2: sales SEK 43m +30% y-o-y, adj. EBIT margin 28% (23%) Raise both '24e-'26e sales and EBIT by 7-5%...
Mangold uppdaterar cybersäkerhetsbolaget Cyber Security 1 (”CYBER1”).
Redeye updates its estimates and valuation after Navigo’s Q2 2024 report.
Redeye provides a research update following the Q2 2024 report from Kancera.
InfraCom’s report was weak, and the company faces a cocktail of headwinds.
Redeye states AVTECH’s report was in line with Redeye Research estimate (RRe) on net sales and a sol...
Q2 sales were in line, EBITDA 11% better Continues to scale well; sales +17%, opex +3% y-o-y Trading...